Prostamax is a research-only peptide bioregulator with no approved human dose. Any figures below are commonly cited and anecdotal, not medically established, and rest on a thin evidence base. This is education, not a personal protocol.
Overview
Prostamax is one of the short "bioregulator" peptides associated with Russian research, discussed in connection with the prostate. It has not completed the controlled clinical trials that would define an effective, tolerable dose, so there is no regulator-approved schedule — only patterns cited within the community.
Commonly cited pattern
Community sources tend to describe a similar shape across bioregulators:
- Roughly 10 mg per day is a commonly cited amount — this is anecdotal, not an established dose.
- Short cycles — typically framed as courses of a few weeks rather than continuous daily use, echoing how the original studies were structured.
- Start low, with supervision — because human data are limited, any cautious framing begins conservatively.
Treat these as a description of what people report, not a recommendation. The supporting evidence is thin, and amounts and cycle lengths are not standardized.
How it is discussed
Bioregulators are commonly described as short courses rather than open-ended daily use. Because there is no approved product or label, there is no verified concentration, no defined route standard, and no established stopping rule — all of which add uncertainty on top of an already limited evidence base.
Why supervision matters
Without trial data, the safety profile, interactions, and appropriate candidates for Prostamax are not well characterized. That is precisely why any real-world decision belongs with a qualified clinician and, where it exists, formal guidance — not a forum figure. The pattern above reflects what is cited, not what has been shown to be safe or effective.